A nationwide cohort study assessing the risk of thromboembolic and ischemic events following COVID-19 vaccination to the risk following infection with SARS-CoV-19
Latest Information Update: 07 Oct 2022
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 07 Oct 2022 New trial record
- 29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology